Related Experiment Videos
CA 125 reliability in predicting ovarian cancer recurrence
F Zanaboni1, M Presti, G Scarfone
1III Clinica Ostetrica e Ginecologica, Università di Milano, Italy.
Tumori
|February 28, 1989
Summary
The CA 125 assay can predict ovarian cancer recurrence. Elevated CA 125 levels detected recurrence earlier in most patients, showing its value in patient follow-up.
Area of Science:
- Oncology
- Clinical Chemistry
Background:
- Ovarian cancer recurrence monitoring is crucial for patient management.
- The CA 125 assay is a commonly used biomarker in ovarian cancer follow-up.
Purpose of the Study:
- To evaluate the predictive value of the CA 125 assay for detecting recurrence in ovarian cancer patients.
- To determine the sensitivity, specificity, and predictive value of elevated CA 125 levels for ovarian cancer relapse.
Main Methods:
- Analysis of 42 ovarian cancer patients with no evidence of disease after treatment.
- Monitoring of CA 125 levels during a median follow-up of 16 months.
- Correlation of CA 125 levels with disease recurrence and relapse timing.
Main Results:
- Elevated CA 125 levels preceded clinical recurrence diagnosis in 13 of 23 patients with relapse, with a median lead time of 5 months.
- The CA 125 assay demonstrated 56% sensitivity and 84% specificity for recurrence.
- The predictive value for recurrence of elevated CA 125 levels was 0.81.
Conclusions:
- The CA 125 assay is a valuable tool for predicting ovarian cancer recurrence.
- Elevated CA 125 levels can provide an early warning for relapse, enabling timely intervention.